FDA approval pathway propels Sangamo Therapeutics shares upward: what’s next?
Sangamo Therapeutics experienced a significant surge in its stock price, jumping by as much as 53%, after the U.S. Food and Drug Administration (FDA) indicated support for an accelerated approval pathway for its gene therapy drug, isaralgagene civaparvovec (ST-920), designed to treat Fabry disease. The FDA’s guidance permits Sangamo to proceed with a streamlined clinical […]